Scholarlink

Background <p>Asthma is the most frequent chronic respiratory disease in childhood and adolescence. While good control can be achieved in the majority of patients with guideline-conform treatment, a&#xa0;relevant subgroup suffer from asthma that is difficult to treat with frequent exacerbations and impaired quality of life.</p> Objective <p>These guidelines aim to clearly define severe and difficult to treat asthma in childhood and adolescence, to promote a&#xa0;structured diagnostic and treatment approach and to provide practical, evidence-based recommendations for the management, including the use of biologicals.</p> Methods <p>The guidelines were developed under the coordination of the Society for Pediatric Pulmonology (GPP) following the Association of Scientific Medical Societies in Germany (AWMF) procedures. A&#xa0;structured consensus process involving experts from pediatric pulmonology, allergology and general pediatrics was conducted. A&#xa0;systematic review of the literature on national and international recommendations was carried out.</p> Results <p>Key elements include a&#xa0;multistage diagnostic approach to distinguish difficult to treat from genuine severe asthma. Criteria for treatment adherence, documentation of comorbidities and phenotype-specific selection of biologicals are presented. Further topics are monitoring, rehabilitation, transition and future forms of treatment. Recommendations on the application of existing and novel monoclonal antibodies are based on the current evidence.</p> Conclusion <p>Children and adolescents with severe asthma require early referral to specialized centers and a&#xa0;structured, interdisciplinary approach. An early phenotype-based treatment with biologicals, comprehensive register data and patient-oriented treatment pathways are necessary in order to improve the prognosis in this group of patients and to generate real-world evidence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Schweres Asthma bei Kindern und Jugendlichen

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Eckard Hamelmann,
  • Christina Schorlemer,
  • Nico Derichs,
  • Ernst Eber,
  • Michael Gerstlauer,
  • Andreas Jung,
  • Michael Kabesch,
  • Matthias Kopp,
  • Susanne Lau,
  • Christiane Lex,
  • Alexander Möller,
  • Bianca Schaub,
  • Nicolaus Schwerk,
  • Thomas Spindler,
  • Christian Taube,
  • Christian Vogelberg,
  • Angela Zacharasiewicz,
  • Stefan Zielen,
  • Antje Schuster,
  • Monika Gappa

摘要

Background

Asthma is the most frequent chronic respiratory disease in childhood and adolescence. While good control can be achieved in the majority of patients with guideline-conform treatment, a relevant subgroup suffer from asthma that is difficult to treat with frequent exacerbations and impaired quality of life.

Objective

These guidelines aim to clearly define severe and difficult to treat asthma in childhood and adolescence, to promote a structured diagnostic and treatment approach and to provide practical, evidence-based recommendations for the management, including the use of biologicals.

Methods

The guidelines were developed under the coordination of the Society for Pediatric Pulmonology (GPP) following the Association of Scientific Medical Societies in Germany (AWMF) procedures. A structured consensus process involving experts from pediatric pulmonology, allergology and general pediatrics was conducted. A systematic review of the literature on national and international recommendations was carried out.

Results

Key elements include a multistage diagnostic approach to distinguish difficult to treat from genuine severe asthma. Criteria for treatment adherence, documentation of comorbidities and phenotype-specific selection of biologicals are presented. Further topics are monitoring, rehabilitation, transition and future forms of treatment. Recommendations on the application of existing and novel monoclonal antibodies are based on the current evidence.

Conclusion

Children and adolescents with severe asthma require early referral to specialized centers and a structured, interdisciplinary approach. An early phenotype-based treatment with biologicals, comprehensive register data and patient-oriented treatment pathways are necessary in order to improve the prognosis in this group of patients and to generate real-world evidence.